Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who have been confirmed by tissue testing to have stage IV non-small cell lung cancer (a type of lung cancer) before starting any treatment
- People who are in generally good physical condition and able to carry out most daily activities (confirm with trial site regarding the specific fitness score required)
- People whose cancer has responded well — either shrinking or staying stable — after 3 cycles (or approximately 3 months) of standard first-line cancer treatment, and who have 5 or fewer remaining cancer spots outside the brain showing on scans
- People who have up to 5 cancer spots in the brain, in addition to those outside the brain, as long as those brain spots can be treated with radiotherapy or surgery
- People whose primary lung tumour and all remaining cancer spots can be treated with surgery or radiotherapy aimed at fully treating each site
- People of reproductive age who agree to use two forms of contraception throughout the study
- People who are able to understand and are willing to follow the trial procedures, confirmed by signing a consent form
Who may not be able to join:
- People who have a serious existing health condition that would make the targeted local treatments (surgery or radiotherapy) unsafe
- People who are still experiencing significant side effects from their initial cancer treatment that have not resolved (confirm with trial site regarding the specific severity level)
- People whose cancer has spread in certain ways, such as causing fluid build-up around the lungs, heart, or abdomen, spreading throughout the bone marrow, spreading to the lining of the brain or spinal cord, spreading widely through the skin or lungs' lymph channels, or forming abdominal masses that cannot be clearly measured on scans
- Women who are currently pregnant or breastfeeding
- People who are already enrolled in another clinical trial that does not allow participation in additional trials, or where joining this trial would place too much burden on the person — though these cases may be reviewed individually by the trial team
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Isabelle Schmitt-Opitz, Prof, Universitätsspital Zürich
Phone: +41 31 389 91 91
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS) l in the Local Ablative Therapy (LAT) arm is superior to Standard of Care (SoC); Quality of life (QoL) in the LAT arm is non-inferior to the control arm as measured with the European Quality of Life 5 Dimensions 3 Level (EQ-5D-5L) questionnaire-based score at 6 months after randomization
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.